FT-Raman and FTIR spectroscopy as a tools showing marker of platinum-resistant phenomena in women suffering from ovarian cancer.
Correlation
FT-Raman
FTIR
Multivariate analyses
Platinum-resistant ovarian cancer
ROC
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 05 2024
14 05 2024
Historique:
received:
02
03
2024
accepted:
09
05
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
epublish
Résumé
Platinum-resistant phenomena in ovarian cancer is very dangerous for women suffering from this disease, because reduces the chances of complete recovery. Unfortunately, until now there are no methods to verify whether a woman with ovarian cancer is platinum-resistant. Importantly, histopathology images also were not shown differences in the ovarian cancer between platinum-resistant and platinum-sensitive tissues. Therefore, in this study, Fourier Transform InfraRed (FTIR) and FT-Raman spectroscopy techniques were used to find chemical differences between platinum-resistant and platinum-sensitive ovarian cancer tissues. Furthermore, Principal Component Analysis (PCA) and machine learning methods were performed to show if it possible to differentiate these two kind of tissues as well as to propose spectroscopy marker of platinum-resistant. Indeed, obtained results showed, that in platinum-resistant ovarian cancer tissues higher amount of phospholipids, proteins and lipids were visible, however when the ratio between intensities of peaks at 1637 cm
Identifiants
pubmed: 38744861
doi: 10.1038/s41598-024-61775-z
pii: 10.1038/s41598-024-61775-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11025Informations de copyright
© 2024. The Author(s).
Références
Hohn, A. K., Brambs, C. H. A., Hiller, G. G. R., May, D., Schmoeckel, E., Horn, L.-C. 2020 WHO Classification of female genital tumors. Geburtshilfe Freuenheilkd. 81, 1145–1153 (2021).
https://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf (accessed 27 Feb 2024).
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021).
doi: 10.3322/caac.21654
pubmed: 33433946
Arora, T., Mullangi, S., Lekkala, M. R. Ovarian cancer. In Stat Pearls (StatPearls Publishing, 2024).
Markowska, J., Mądry, R. Zarys ginekologii onkologicznej (Termedia sp. z o.o., 2021).
Davis, A., Tinker, A. V. & Friedlander, M. “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?. Gynecol. Oncol. 133, 624–631 (2014).
doi: 10.1016/j.ygyno.2014.02.038
pubmed: 24607285
Friendlander, M. et al. Clinical trials in recurrent ovarian cancer. Int. J. Gynecol. Cancer 21, 771–775 (2011).
doi: 10.1097/IGC.0b013e31821bb8aa
Stuart, G. C. E. et al. 2010 Gynecologic cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the Fourth Ovarian Cancer Consensus Conference. Int. J. Gynecol. Cancer 21, 750–755 (2011).
doi: 10.1097/IGC.0b013e31821b2568
pubmed: 21543936
Dasari, S. & Tchounwou, P. B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 740, 364–378 (2014).
doi: 10.1016/j.ejphar.2014.07.025
pubmed: 25058905
pmcid: 4146684
Zhou, J. et al. The drug-resistance mechanisms of five platinum-based antitumor agents. Front. Pharmacol. 11, 343 (2020).
doi: 10.3389/fphar.2020.00343
pubmed: 32265714
pmcid: 7100275
Depciuch, J. et al. Spectroscopic analysis of normal and neoplastic (WI-FTC) thyroid tissue. Spectrochim. Acta A Mol. Biomol. Spectrosc. 204, 18–24 (2018).
doi: 10.1016/j.saa.2018.06.010
pubmed: 29902767
Taylor, E. A. & Donnelly, E. Raman and Fourier transform infrared imaging for characterization of bone material properties. Bone 139, 115490 (2020).
doi: 10.1016/j.bone.2020.115490
pubmed: 32569874
Chaber, R. et al. Distinguishing Ewing sarcoma and osteomyelitis using FTIR spectroscopy. Sci. Rep. 8, 15081 (2018).
doi: 10.1038/s41598-018-33470-3
pubmed: 30305666
pmcid: 6180062
Bukłaho, P. A., Kiśluk, J., Wasilewska, N. & Nikliński, J. Molecular features as promising biomarkers in ovarian cancer. Adv. Clin. Exp. Med. 32, 1029–1040 (2023).
doi: 10.17219/acem/159799
pubmed: 36920264
Atallah, G. A. et al. Predicting prognosis and platinum resistance in ovarian cancer: Role of immunohistochemistry biomarkers. Int. J. Mol. Sci. 24, 1973 (2023).
doi: 10.3390/ijms24031973
pubmed: 36768291
pmcid: 9916805
Krishna, C. M. et al. FTIR and Raman microspectroscopy of normal, benign, and malignant formalin-fixed ovarian tissues. Anal. Bioanal. Chem. 387, 1649–1656 (2007).
doi: 10.1007/s00216-006-0827-1
pubmed: 17043798
Bonnier, F., Baker, M. J. & Byrne, H. J. Vibrational spectroscopic analysis of body fluids: Avoiding molecular contamination using centrifugal filtration. Anal. Methods 6, 5155 (2014).
doi: 10.1039/c4ay00891j
Liu, K.-Z. et al. Reagent-free, simultaneous determination of serum cholesterol in HDL and LDL by infrared spectroscopy. Clin. Chem. 48(3), 499–506 (2002).
doi: 10.1093/clinchem/48.3.499
pubmed: 11861440
Dong, L., Shaw, R. A., Man, A., Dembinski, T. C. & Mantschl, H. H. Evaluation of FTIR spectroscopy as diagnostic tool for colorectal cancer using spectral analysis. Spectrochim. Acta A Mol. Biomol. Spectrosc. 122, 288–294 (2014).
doi: 10.1016/j.saa.2013.11.031
pubmed: 24316544
Li, L. et al. Characterization of ovarian cancer cells and tissues by Fourier transform infrared spectroscopy. J. Ovarian Res. 11, 64 (2018).
doi: 10.1186/s13048-018-0434-8
pubmed: 30071867
pmcid: 6090913
Wang, Q. et al. UV-Vis and ATR-FTIR spectroscopic investigations of postmortem interval based on the changes in rabbit plasma. PLoS One 12, e0182161 (2017).
doi: 10.1371/journal.pone.0182161
pubmed: 28753641
pmcid: 5533326
Yoshida, S. & Yoshida, H. Nondestructive analyses of unsaturated fatty acid species in dietary oils by attenuated total reflectance with Fourier transform IR spectroscopy. Biopolymers 70, 604–613 (2003).
doi: 10.1002/bip.10505
pubmed: 14648770
Ferreira, I. C. C. et al. Attenuated total reflection—Fourier transform inrfared (ATR-FTIR) spectroscopy analysis of saliva for breast cancer diagnosis. J. Oncol. 10, 4343590 (2020).
Auner, G. W. et al. Applications of Raman spectroscopy in cancer diagnosis. Cancer Metastasis Rev. 37, 691–717 (2018).
doi: 10.1007/s10555-018-9770-9
pubmed: 30569241
pmcid: 6514064
Abramczyk, H. et al. The role of lipid droplets and adipocytes in cancer. Raman imaging of cell cultures: MCF10A, MCF7, and MDA-MB-231 compared to adipocytes in cancerous human breast tissue. Analyst 140, 2224–2235 (2015).
doi: 10.1039/C4AN01875C
pubmed: 25730442
Havasi, A., Cainap, S. S., Havasi, A. T. & Cainap, C. Ovarian cancer—Insight into platinum resistance and overcoming it. Medicina (Kaunas) 59, 544 (2023).
doi: 10.3390/medicina59030544
pubmed: 36984544
Ghoneum, A. et al. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer. Semin. Cancer Biol. 77, 83–98 (2021).
doi: 10.1016/j.semcancer.2020.12.024
pubmed: 33476723
pmcid: 8286277
Sassu, C. M. et al. Role of circulating biomarkers in platinum-resistance ovarian cancer. Int. J. Mol. Sci. 22, 13650 (2021).
doi: 10.3390/ijms222413650
pubmed: 34948446
pmcid: 8707281
Moore, R. G. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with pelvic mass. Gynecol. Oncol. 112, 40–46 (2009).
doi: 10.1016/j.ygyno.2008.08.031
pubmed: 18851871
Boivin, M., Lane, D., Piche, A. & Rancourt, C. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol. Oncol. 115, 407–413 (2009).
doi: 10.1016/j.ygyno.2009.08.007
pubmed: 19747716
James, N. E., Chichester, C. & Ribeiro, J. R. Beyond the biomarker: Understanding the diverse roles of human epididymis protein 4 in the pathogenesis of epithelial ovarian cancer. Front. Oncol. 8, 124 (2018).
doi: 10.3389/fonc.2018.00124
pubmed: 29740539
pmcid: 5928211
Ribeiro, J. R. et al. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells. J. Ovarian Res. 9, 28 (2016).
doi: 10.1186/s13048-016-0240-0
pubmed: 27184254
pmcid: 4869286
Angioli, R. et al. Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?. Tumour Biol. 35, 7009–7015 (2014).
doi: 10.1007/s13277-014-1836-x
pubmed: 24748235
Lv, J. & Li, P. Mesothelin as a biomarker for targeted therapy. Biomark. Res. 7, 18 (2019).
doi: 10.1186/s40364-019-0169-8
pubmed: 31463062
pmcid: 6708176
Gharpure, K. M. et al. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat. Commun. 9, 2923 (2018).
doi: 10.1038/s41467-018-04987-y
pubmed: 30050129
pmcid: 6062524
https://polpat.pl/pliki/files/wytyczne_i_standardy/standardy/04_standardy_tresc_ksiazki.pdf (accessed 27 Feb 2024).
Vapnik, V. N. Statistical Learning Theory (Wiley, 1998).
Chen, T., Guestrin, C. XGBoost: A scalable tree boosting system. In KDD’16: Proceedings of the 22
Altman, N. S. An introduction to kernel and nearest-neighbor nonparametric regression. Am. Stat. 46, 175–185 (1992).
doi: 10.1080/00031305.1992.10475879
Paja, W. Feature selection methods based on decision rule and tree models. In Intelligent Decision Technologies (eds. Czarnowski, I., et al.) (Springer, 2016).